AXCYNSIS AXCYNSIS THERAPEUTICS Trademark
Trademark Overview
On Tuesday, July 23, 2024, a trademark application was filed for AXCYNSIS AXCYNSIS THERAPEUTICS with the United States Patent and Trademark Office. The USPTO has given the AXCYNSIS AXCYNSIS THERAPEUTICS trademark a serial number of 79407408. The federal status of this trademark filing is PUBLICATION/ISSUE REVIEW COMPLETE as of Tuesday, August 12, 2025. This trademark is owned by AXCYNSIS THERAPEUTICS PTE. LTD.. The AXCYNSIS AXCYNSIS THERAPEUTICS trademark is filed in the Pharmaceutical Products, Computer & Software Services & Scientific Services, and Medical & Beauty Services & Agricultural Services categories with the following description:
Pharmaceutical preparations for use in oncology; pharmaceutical drugs being pharmaceutical preparations for use in the treatment of cancer; pharmaceutical products, namely, pharmaceutical preparations for suppressing tumors; biopharmaceutical preparations for the treatment of cancer; chemical preparations for pharmaceutical purposes, namely, for oncology.
Medical testing services in the nature of in vitro testing for medical diagnostic and treatment purposes and in vitro testing of pharmaceuticals; medical analysis services in the nature of in vitro analysis for medical diagnostic and treatment purposes and in vitro analysis in the nature of testing, inspection, or research of pharmaceuticals.
Development of pharmaceuticals; pharmaceutical research and development; research and development for the pharmaceutical industry; biochemical research; biochemical research and analysis; biochemical research and development; biochemistry research services; bioinorganic chemistry research; biological research; biological research and analysis; biological research laboratory services; biological research services; biomedical research services; bioorganic chemistry research; biotechnological research; biotechnology research; chemical research; chemical research and analysis; chemical research and analysis services; chemical research laboratory services; chemical research services; technological research in the field of chemistry; chemistry research; clinical research in the field of antibody drug conjugates in oncology; consultancy in the field of pharmaceutical research; consultancy in the field of scientific research; consultancy in the field of technological research relating to pharm...
General Information
| Serial Number | 79407408 |
| Word Mark | AXCYNSIS AXCYNSIS THERAPEUTICS |
| Filing Date | Tuesday, July 23, 2024 |
| Status | 681 - PUBLICATION/ISSUE REVIEW COMPLETE |
| Status Date | Tuesday, August 12, 2025 |
| Registration Number | 0000000 |
| Registration Date | NOT AVAILABLE |
| Mark Drawing | 3 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s) |
| Published for Opposition Date | NOT AVAILABLE |
Trademark Statements
| Description of Mark | The mark consists of the stylized wording "AXCYNSIS" in which the lettering "AXC" is formed by a blue geometric figure with connecting diagonal and horizontal lines resembling a molecular model, the letter "Y" appears in teal and is angled to one side and surrounded by two teal diagonal lines also resembling an Antibody, and the lettering "NSIS" appears in teal stylized font. All of the foregoing appears above the stylized black wording "AXCYNSIS THERAPEUTICS". The color white represents background and is not claimed as a feature of the mark. |
| Goods and Services | Pharmaceutical preparations for use in oncology; pharmaceutical drugs being pharmaceutical preparations for use in the treatment of cancer; pharmaceutical products, namely, pharmaceutical preparations for suppressing tumors; biopharmaceutical preparations for the treatment of cancer; chemical preparations for pharmaceutical purposes, namely, for oncology. |
| Indication of Colors claimed | The color(s) blue, teal and black is/are claimed as a feature of the mark. |
| Goods and Services | Medical testing services in the nature of in vitro testing for medical diagnostic and treatment purposes and in vitro testing of pharmaceuticals; medical analysis services in the nature of in vitro analysis for medical diagnostic and treatment purposes and in vitro analysis in the nature of testing, inspection, or research of pharmaceuticals. |
| NOT AVAILABLE | "THERAPEUTICS" |
| Goods and Services | Development of pharmaceuticals; pharmaceutical research and development; research and development for the pharmaceutical industry; biochemical research; biochemical research and analysis; biochemical research and development; biochemistry research services; bioinorganic chemistry research; biological research; biological research and analysis; biological research laboratory services; biological research services; biomedical research services; bioorganic chemistry research; biotechnological research; biotechnology research; chemical research; chemical research and analysis; chemical research and analysis services; chemical research laboratory services; chemical research services; technological research in the field of chemistry; chemistry research; clinical research in the field of antibody drug conjugates in oncology; consultancy in the field of pharmaceutical research; consultancy in the field of scientific research; consultancy in the field of technological research relating to pharmaceutical studies; consultancy relating to pharmaceutical research and development; consultancy relating to pharmaceutical research and development in the field of therapeutics; DNA analysis services for scientific research purposes; DNA screening for scientific research purposes; DNA sequencing being DNA analysis for medical research purposes; DNA sequencing technology research; gene therapy research; scientific research in the field of genetics and antibody drug conjugates; genetic testing for scientific research purposes; laboratory research in the fields of antibody drug conjugates in oncology and antibody drug conjugate development; laboratory research in the field of chemistry; laboratory research in the field of gene expression; laboratory research in the field of pharmaceuticals; laboratory research services relating to pharmaceuticals; medical research; medical research in the field of oncology; medical research laboratory services; medical research services; pharmaceutical research and development services; pharmaceutical research consultancy; pharmaceutical research services; chemical research services in the nature of preparation of scientific reports relating to chemical research; scientific research services in the nature of preparation of scientific reports relating to scientific research; product research; product research and development; providing information about medical and scientific research in the field of pharmaceuticals; providing information relating to scientific research in the fields of biochemistry and biotechnology; providing information and online information about scientific and technological services in the field of antibody drug conjugates in oncology and research and design relating thereto; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; provision of information relating to scientific research; provision of information relating to technological research in the field of antibody drug conjugates in oncology; research services, namely, scientific research; research and development in the field of biotechnology; research and development of new products; research and development of new products for others; research and development services for the pharmaceutical industry; research and development services in the field of antibodies; research and development services in the field of antibody technology; research and development services in the field of biochemistry; research and development services in the field of biotechnology; research and development services in the field of chemistry; research and development services in the field of pharmaceutical preparations; research in the field of biology; research in the field of biomedicine; research in the field of biotechnology; research in the field of chemistry; research on the subject of pharmaceuticals; research relating to biotechnology; research relating to chemistry; research relating to chemicals; research relating to medicine in the nature of medical research; research relating to molecular sciences; research relating to pharmaceuticals; research relating to science; research laboratory analysis services in the field of chemistry and bioconjugation; research to develop new products; scientific and industrial research in the field of antibody drug conjugates in oncology; scientific and technological services, namely, research and design in the field of antibody drug conjugates in oncology; scientific and technological services, namely, research and development in the field of antibody drug conjugates in oncology; scientific research; scientific research and analysis for scientific research purposes; scientific research and development; scientific research for medical purposes; scientific research for medical purposes in the area of cancerous diseases; scientific research in the field of biotechnology; scientific research into the development of new products; scientific research relating to biology; scientific research relating to chemistry; scientific research relating to chemical products; scientific research relating to genetics; scientific research services; technical research in the field of pharmaceutical studies; technical research projects and studies in the field of antibody drug conjugates in oncology. |
Classification Information
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 005, 006, 018, 044, 046, 051, 052 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, October 24, 2024 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 042 - Scientific and technological services and research and design relating thereto; industrial analysis and research services; design and development of computer hardware and software. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, October 24, 2024 |
| Primary Code | 042 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. |
| US Class Codes | 100, 101 |
| Class Status Code | 6 - Active |
| Class Status Date | Thursday, October 24, 2024 |
| Primary Code | 044 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
Trademark Owner History
| Party Name | AXCYNSIS THERAPEUTICS PTE. LTD. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 24 - NOT AVAILABLE |
| Address | SG |
Trademark Events
| Event Date | Event Description |
| Thursday, October 24, 2024 | SN ASSIGNED FOR SECT 66A APPL FROM IB |
| Friday, November 8, 2024 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED |
| Friday, January 10, 2025 | ASSIGNED TO EXAMINER |
| Friday, November 8, 2024 | APPLICATION FILING RECEIPT MAILED |
| Wednesday, January 15, 2025 | NON-FINAL ACTION WRITTEN |
| Thursday, January 16, 2025 | NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW |
| Tuesday, March 4, 2025 | NON-FINAL ACTION MAILED - REFUSAL SENT TO IB |
| Tuesday, March 4, 2025 | REFUSAL PROCESSED BY MPU |
| Saturday, March 22, 2025 | REFUSAL PROCESSED BY IB |
| Thursday, July 24, 2025 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Thursday, July 24, 2025 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Friday, July 25, 2025 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Monday, July 28, 2025 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Monday, July 28, 2025 | EXAMINERS AMENDMENT -WRITTEN |
| Monday, July 28, 2025 | EXAMINERS AMENDMENT E-MAILED |
| Monday, July 28, 2025 | EXAMINER'S AMENDMENT ENTERED |
| Tuesday, July 29, 2025 | APPROVED FOR PUB - PRINCIPAL REGISTER |
